Publicacions en què col·labora amb Marcos González Díaz (11)

2016

  1. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion

    Leukemia Research, Vol. 46, pp. 30-36

  2. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2015

  1. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia

    BioMed Research International, Vol. 2014

2013

  1. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling

    Annals of Oncology, Vol. 23, Núm. 8, pp. 2138-2146

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

  2. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

2009

  1. A high number of losses in 13ql4 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia

    Haematologica, Vol. 94, Núm. 3, pp. 364-371

  2. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  3. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152